

General Information	
Ministerial Decision Type	Miscellaneous
Report Title	Amendment to the Prescribed List as of 1 January 2025
Minister	Social Security
Signatory	Minister
Lead Department	Strategic Policy, Planning and Performance (SP3)
Lead Directorate	Public Policy (SP3)
Ministerial Decision Summary: Public or Absolutely/Qualified Exempt	Public Select if more than one Absolutely/Qualified Exemption.
Date decision made if different to date 'Ministerial Decision Summary' signed.	Select date.
Report and Supplemental Report Details	
Report Author	Senior Policy Officer
Date of Report	20/11/2024
Supplementary Report Title <i>(If applicable)</i>	SD PBAC November 2024
Supplementary Report Author <i>(If applicable)</i>	Prescribing Advisor
Date of Supplementary Report <i>(If applicable)</i>	20/11/2024
Ministerial Decision Report: Public or Absolutely/Qualified Exempt	Public Select if more than one Absolutely/Qualified Exemption.
Relevant Case/Application/URN <i>(Only complete if making a decision related to an appeal where appropriate or allowed under legislation/case/application)</i>	Insert Relevant Case/Application.
Relevant Proposition Number <i>(Only complete if presenting Comments or if lodging an Amendment)</i>	Insert P. number.
Relevant Scrutiny Report <i>(Only complete if presenting a ministerial response)</i>	Insert S.R. number.
Associated Law(s) and/or Subordinate Legislation	Health Insurance (Jersey) Law 1967
Action required if recommendation agreed	Department to take necessary action.

Resource Implications	There are no new financial and/or manpower implications.
-----------------------	--

Introduction

Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 January 2025

Recommendation

Other

Only insert text if 'Other' selected above.

The Minister accepted recommendations from the PBAC in respect of the following additions and deletions.

1. Additions

- **Tacrolimus 2mg capsules**
- **Bupivacaine Hydrochloride** 0.5% w/v solution for injection; **bupivacaine** 50mg/10ml (0.5%) / **adrenaline** (base) 50micrograms/10ml (1 in 200,000) solution for injection ampoules
- **Tirzepatide** solution for injection 2.4ml pre-filled disposable devices – 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg

2. Deletions

- Adrenaline 500micrograms/0.5mL (1 in 1,000) solution for injection auto-injectors (Brand names: Minijet or Emerade)
- Klean-Prep oral powder 69g sachets
- Cefaclor 125mg/5mL and 250mg/5mL oral suspension sugar free
- Co-amoxiclav 125mg/31mg/5ml & 250mg/62mg/5ml oral suspension (non-sugar free)
- Colecalciferol 800unit / Calcium phosphate 3.1g oral powder sachets
- Diphtheria / Tetanus vaccine (adsorbed) suspension for injection 0.5ml pre-filled syringes
- Erythromycin ethyl succinate 500mg/5ml oral suspension sugar free
- Hydrocortisone 1% / Miconazole 2% ointment
- Menthol and Eucalyptus inhalation
- Artificial saliva lozenges
- Ancora® 375 Ag and
- Multiload® Cu375
- Colecalciferol 800unit / calcium phosphate 3.1g oral powder sachets
- Potassium chloride 375mg/5mL (potassium 5mmol/5mL) oral solution SF
- Fluocinolone acetonide 0.00625% cream
- Cimetidine 200mg/5ml oral suspension sugar free – special order products only available
- Novaplus T 380 Ag; Novaplus T 380 Cu – renamed as Eurogine T 380 Ag and Eurogine T 380 Cu
- Povidone-Iodine 10% antiseptic solution – rarely used item

Financial impact

Ministerial Office
Ministerial Decision Report



The recommended changes to the Prescribed List are estimated to result in an increase in expenditure of up to around £201,500.